Johnson & Johnson Quick Ratio 2010-2024 | JNJ
Historical quick ratio values for Johnson & Johnson (JNJ) over the last 10 years.
| Johnson & Johnson Quick Ratio Historical Data |
| Date |
Current Assets - Inventory |
Current Liabilities |
Quick Ratio |
| 2024-09-30 |
$40.65B |
$51.76B |
0.79 |
| 2024-06-30 |
$45.65B |
$53.93B |
0.85 |
| 2024-03-31 |
$45.62B |
$48.73B |
0.94 |
| 2023-12-31 |
$42.31B |
$46.28B |
0.91 |
| 2023-09-30 |
$42.51B |
$44.37B |
0.96 |
| 2023-06-30 |
$47.68B |
$54.17B |
0.88 |
| 2023-03-31 |
$51.58B |
$60.37B |
0.85 |
| 2022-12-31 |
$45.03B |
$55.80B |
0.81 |
| 2022-09-30 |
$53.56B |
$45.54B |
1.18 |
| 2022-06-30 |
$52.41B |
$44.82B |
1.17 |
| 2022-03-31 |
$49.43B |
$43.39B |
1.14 |
| 2021-12-31 |
$50.59B |
$45.23B |
1.12 |
| 2021-09-30 |
$49.50B |
$44.56B |
1.11 |
| 2021-06-30 |
$43.67B |
$38.72B |
1.13 |
| 2021-03-31 |
$42.58B |
$40.93B |
1.04 |
| 2020-12-31 |
$41.89B |
$42.49B |
0.99 |
| 2020-09-30 |
$47.98B |
$38.85B |
1.24 |
| 2020-06-30 |
$36.47B |
$36.77B |
0.99 |
| 2020-03-31 |
$35.36B |
$33.69B |
1.05 |
| 2019-12-31 |
$36.25B |
$35.96B |
1.01 |
| 2019-09-30 |
$35.16B |
$35.16B |
1.00 |
| 2019-06-30 |
$32.54B |
$31.35B |
1.04 |
| 2019-03-31 |
$32.90B |
$29.11B |
1.13 |
| 2018-12-31 |
$37.43B |
$31.23B |
1.20 |
| 2018-09-30 |
$38.52B |
$27.44B |
1.40 |
| 2018-06-30 |
$36.63B |
$27.49B |
1.33 |
| 2018-03-31 |
$33.75B |
$27.08B |
1.25 |
| 2017-12-31 |
$34.32B |
$30.54B |
1.12 |
| 2017-09-30 |
$32.31B |
$31.81B |
1.02 |
| 2017-06-30 |
$29.09B |
$28.87B |
1.01 |
| 2017-03-31 |
$54.47B |
$25.12B |
2.17 |
| 2016-12-31 |
$56.89B |
$26.29B |
2.16 |
| 2016-09-30 |
$54.83B |
$23.23B |
2.36 |
| 2016-06-30 |
$57.77B |
$21.54B |
2.68 |
| 2016-03-31 |
$54.57B |
$22.13B |
2.47 |
| 2015-12-31 |
$52.16B |
$27.75B |
1.88 |
| 2015-09-30 |
$55.29B |
$25.26B |
2.19 |
| 2015-06-30 |
$52.70B |
$24.51B |
2.15 |
| 2015-03-31 |
$50.11B |
$23.84B |
2.10 |
| 2014-12-31 |
$47.56B |
$25.03B |
1.90 |
| 2014-09-30 |
$51.55B |
$22.98B |
2.24 |
| 2014-06-30 |
$51.96B |
$24.36B |
2.13 |
| 2014-03-31 |
$49.36B |
$23.84B |
2.07 |
| 2013-12-31 |
$48.53B |
$25.68B |
1.89 |
| 2013-09-30 |
$44.05B |
$25.84B |
1.71 |
| 2013-06-30 |
$43.45B |
$23.77B |
1.83 |
| 2013-03-31 |
$39.54B |
$22.52B |
1.76 |
| 2012-12-31 |
$38.62B |
$24.26B |
1.59 |
| 2012-09-30 |
$36.98B |
$23.94B |
1.55 |
| 2012-06-30 |
$33.92B |
$23.85B |
1.42 |
| 2012-03-31 |
$50.21B |
$21.20B |
2.37 |
| 2011-12-31 |
$48.03B |
$22.81B |
2.11 |
| 2011-09-30 |
$47.02B |
$21.69B |
2.17 |
| 2011-06-30 |
$46.26B |
$20.99B |
2.20 |
| 2011-03-31 |
$43.02B |
$24.01B |
1.79 |
| 2010-12-31 |
$41.93B |
$23.07B |
1.82 |
| 2010-09-30 |
$37.31B |
$17.41B |
2.14 |
| 2010-06-30 |
$33.95B |
$17.16B |
1.98 |
| 2010-03-31 |
$33.55B |
$18.50B |
1.81 |
| 2009-12-31 |
$34.36B |
$21.73B |
1.58 |
| 2009-09-30 |
$30.03B |
$19.25B |
1.56 |
| 2009-06-30 |
$30.02B |
$19.89B |
1.51 |
| 2009-03-31 |
$29.48B |
$21.33B |
1.38 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$385.533B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
